Literature DB >> 21896789

Biosynthesis and identification of an N-oxide/N-glucuronide metabolite and first synthesis of an N-O-glucuronide metabolite of Lu AA21004.

Henriette Kold Uldam1, Martin Juhl, Henrik Pedersen, Lars Dalgaard.   

Abstract

This article describes the biosynthesis and identification of a new class of metabolites, a piperazine N-oxide/N-glucuronide metabolite 4-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-1-β-D-glucuronic acid-piperazine 1-oxide (4). The metabolite was found in urine and plasma from humans and animals dosed with 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrobromide (Lu AA21004, 1), as a novel multimodal antidepressant under development for treatment of depression. Human liver microsomes in combination with uridine 5'-diphosphoglucuronic acid were used as an in vitro system to generate enough material of 4 to perform one- and two-dimensional (1)H and (13)C NMR experiments for structure elucidation. Based on rotating frame Overhauser enhancement spectroscopy NMR experiments, the distance correlation between a piperazine proton and the anomeric proton of the glucuronic acid moiety is of a magnitude similar to that of the H-3' and H-5' protons and can only be explained by proximity in space and the postulated structure (4). The structural analog, the N-O-glucuronic acid conjugate 6-{4-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazin-1-yloxy}-1-β-D-glucuronic acid (3) was also observed in biological samples from humans and animals and the first organic synthesis and structural identification of this metabolite is also reported. Treatment of the glucuronide metabolites 3 and 4 with β-glucuronidase gave mainly the expected hydrolysis product, the hydroxyl amine 4-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazin-1-ol (2).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21896789     DOI: 10.1124/dmd.111.040428

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  5 in total

1.  Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation.

Authors:  Ariane Wohlfarth; Karl B Scheidweiler; Shaokun Pang; Mingshe Zhu; Marisol Castaneto; Robert Kronstrand; Marilyn A Huestis
Journal:  Drug Test Anal       Date:  2015-09-01       Impact factor: 3.345

2.  Vortioxetine: first global approval.

Authors:  Andrew Gibb; Emma D Deeks
Journal:  Drugs       Date:  2014-01       Impact factor: 9.546

3.  Characterization of Clofazimine Metabolism in Human Liver Microsomal Incubation In Vitro.

Authors:  Saurav Howlader; Min-Jung Kim; M Rasheduzzaman Jony; Nguyen Phuoc Long; Yong-Soon Cho; Dong-Hyun Kim; Jae-Gook Shin
Journal:  Antimicrob Agents Chemother       Date:  2022-10-03       Impact factor: 5.938

Review 4.  Vortioxetine: Clinical Pharmacokinetics and Drug Interactions.

Authors:  Grace Chen; Astrid-Maria Højer; Johan Areberg; George Nomikos
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

5.  Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes.

Authors:  Xingxing Diao; Karl B Scheidweiler; Ariane Wohlfarth; Mingshe Zhu; Shaokun Pang; Marilyn A Huestis
Journal:  Forensic Toxicol       Date:  2016-03-28       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.